早发乳腺癌全球现状:从风险评估到精准预防与癌症拦截
Global landscape of early-onset breast cancer: from understanding risk to precision prevention and cancer interception
本文综述早发乳腺癌的全球负担、风险因素、遗传检测与精准预防策略。研究指出早发乳腺癌在发病率、分子亚型分布及生存率上与老年患者存在差异,BRCA1/2及其他易感基因突变检出率较高,建议结合多基因风险评分和循环肿瘤DNA(ctDNA)进行个体化风险分层与微小残留病监测,以提升早期筛查与干预效果。
Kim, J. et al. Global patterns and trends in breast cancer incidence and mortality across 185 countries. Nat. Med. 31, 1154–1162 https://doi.org/10.1038/s41591-025-03502-3 (2025).
Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229–263 https://doi.org/10.3322/caac.21834 (2024).
Sung, H. et al. Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries. CA Cancer J. Clin. 76, e70090 https://doi.org/10.3322/caac.70090 (2026).
Li, N. H. Y. & Li, C. I. Incidence rate trends of breast cancer overall and by molecular subtype by race and ethnicity and age. JAMA Netw. Open 8, e2456142 https://doi.org/10.1001/jamanetworkopen.2024.56142 (2025).
Gupta, A. & Akinyemiju, T. Early-onset cancer incidence in the United States by race/ethnicity between 2011 and 2020. Cancer Epidemiol. 92, 102632 https://doi.org/10.1016/j.canep.2024.102632 (2024).
Humlevik, R. O. C. et al. Distinct clinicopathological features and treatment differences in breast cancer patients of young age. Sci. Rep. 15, 5655 https://doi.org/10.1038/s41598-025-90053-9 (2025).
Santucci, C. et al. Trends in cancer mortality under age 50 in 15 upper-middle and high-income countries. J. Natl Cancer Inst. 117, 747–760 https://doi.org/10.1093/jnci/djae288 (2025).
Jayasekera, J. et al. Breast cancer mortality by age and race and/or ethnicity across counties in the United States, 2000-2019. J. Natl Cancer Inst. 118, 1705–1714 https://doi.org/10.1093/jnci/djag103 (2026).
Patel, V. R., Adamson, A. S. & Welch, H. G. The rise in early-onset cancer in the US population — more apparent than real. JAMA Intern. Med. 185, 1370–1374 https://doi.org/10.1001/jamainternmed.2025.4917 (2025).
Xu, S., Murtagh, S., Han, Y., Wan, F. & Toriola, A. T. Breast cancer incidence among US women aged 20 to 49 years by race, stage, and hormone receptor status. JAMA Netw. Open 7, e2353331 https://doi.org/10.1001/jamanetworkopen.2023.53331 (2024).
Galukande, M. et al. Maternally orphaned children and intergenerational concerns associated with breast cancer deaths among women in sub-Saharan Africa. JAMA Oncol. 7, 285–289 https://doi.org/10.1001/jamaoncol.2020.6583 (2021).
Guida, F. et al. Global and regional estimates of orphans attributed to maternal cancer mortality in 2020. Nat. Med. 28, 2563–2572 https://doi.org/10.1038/s41591-022-02109-2 (2022).
Bedrosian, I. et al. Germline testing in patients with breast cancer: ASCO–Society of Surgical Oncology Guideline. J. Clin. Oncol. 42, 584–604 https://doi.org/10.1200/jco.23.02225 (2024).
Roberts, E., Howell, S. & Evans, D. G. Polygenic risk scores and breast cancer risk prediction. Breast 67, 71–77 https://doi.org/10.1016/j.breast.2023.01.003 (2023).
Lamb, L. R., Mercaldo, S. F., Carney, A. & Lehman, C. D. A deep learning breast cancer risk model for precise supplemental screening. JAMA Netw. Open 9, e2610559 https://doi.org/10.1001/jamanetworkopen.2026.10559 (2026).
Brantley, K. D. et al. Tumor genomics in patients younger than 40 years of age with metastatic breast cancer. NPJ Precis. Oncol. 10, 144 https://doi.org/10.1038/s41698-026-01333-0 (2026).
Reid, S., Spalluto, L. & Pal, T. Breast cancer risk stratification in Black women: current status and potential solutions to improve accuracy. J. Natl Compr. Canc Netw. 24, e257079 https://doi.org/10.6004/jnccn.2025.7079 (2025).
Lambertini, M. et al. Clinical behavior of breast cancer in young BRCA carriers and prediagnostic awareness of germline BRCA status. J. Clin. Oncol. 43, 1706–1719 https://doi.org/10.1200/JCO-24-01334 (2025).
Piccart, M. et al. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. Lancet Oncol. 22, 476–488 https://doi.org/10.1016/S1470-2045(21)00007-3 (2021).
Schlam, I., Tolaney, S. M., Lin, N. U., Parsons, H. & Morganti, S. Circulating tumor DNA in early breast cancer. JAMA Oncol. 12, 773–784 https://doi.org/10.1001/jamaoncol.2026.1465 (2026).
Sisca, L. et al. Prognostic significance of circulating tumor DNA in early breast cancer: a systematic review and meta-analysis. Breast Cancer Res. Treat. 216, 16 https://doi.org/10.1007/s10549-026-07919-3 (2026).
Hunter, N. B. et al. The pathologic response evaluation and detection in circulating tumor-DNA study: ultrasensitive circulating tumor-DNA assessment of breast cancer minimal residual disease. J. Clin. Oncol. 44, 1283–1295 https://doi.org/10.1200/JCO-25-02934 (2026).
Medford, A. J. et al. Molecular residual disease in breast cancer: detection and therapeutic interception. Clin. Cancer Res. 29, 4540–4548 https://doi.org/10.1158/1078-0432.CCR-23-0757 (2023).
Di Cosimo, S. et al. Circulating tumor DNA in early breast cancer: evidence, challenges, next steps. Cancer 132, e70521 https://doi.org/10.1002/cncr.70521 (2026).
Cohen, S. A., Liu, M. C. & Aleshin, A. Practical recommendations for using ctDNA in clinical decision making. Nature 619, 259–268 https://doi.org/10.1038/s41586-023-06225-y (2023).
Villarreal-Garza, C. et al. Clinical utility of genomic signatures in young breast cancer patients: a systematic review. NPJ Breast Cancer 6, 46 https://doi.org/10.1038/s41523-020-00188-3 (2020).
Lobo-Martins, S., Luen, S. J., Piccart, M. & Loi, S. Tailoring targeted therapies for younger women with ER-positive early-stage breast cancer. Nat. Rev. Clin. Oncol. 23, 297–315 https://doi.org/10.1038/s41571-026-01120-7 (2026).
Licata, L. et al. Real-world use of multigene signatures in early breast cancer: differences to clinical trials. Breast Cancer Res. Treat. 205, 39–48 https://doi.org/10.1007/s10549-023-07227-0 (2024).
Wang, W. et al. Global, regional, and national burden of breast cancer in young women from 1990 to 2021: findings from the Global Burden of Disease Study 2021. BMC Cancer 25, 1015 https://doi.org/10.1186/s12885-025-14416-1 (2025).
Global Burden of Disease Study Collaborators. Global, regional, and national burden of breast cancer among females, 1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023. Lancet Oncol. 27, 302–326 https://doi.org/10.1016/S1470-2045(25)00730-2 (2026).
Cai, Y., Dai, F., Ye, Y. & Qian, J. The global burden of breast cancer among women of reproductive age: a comprehensive analysis. Sci. Rep. 15, 9347 https://doi.org/10.1038/s41598-025-93883-9 (2025).
Valencia, O. M. et al. The role of genetic testing in patients with breast cancer: a review. JAMA Surg. 152, 589–594 https://doi.org/10.1001/jamasurg.2017.0552 (2017).
Acheampong, T., Kehm, R. D., Terry, M. B., Argov, E. L. & Tehranifar, P. Incidence trends of breast cancer molecular subtypes by age and race/ethnicity in the US from 2010 to 2016. JAMA Netw. Open 3, e2013226 https://doi.org/10.1001/jamanetworkopen.2020.13226 (2020).
Walsh, T. et al. Genetic predisposition to breast cancer due to mutations other than BRCA1 and BRCA2 founder alleles among Ashkenazi Jewish women. JAMA Oncol. 3, 1647–1653 https://doi.org/10.1001/jamaoncol.2017.1996 (2017).
Lipsyc-Sharf, M. et al. Age, body mass index, tumor subtype, and racial and ethnic disparities in breast cancer survival. JAMA Netw. Open 6, e2339584 https://doi.org/10.1001/jamanetworkopen.2023.39584 (2023).
Patel, V. R., Adamson, A. S. & Welch, H. G. The rise in early-onset cancer in the US population-more apparent than real. JAMA Intern. Med. 185, 1370–1374 https://doi.org/10.1001/jamainternmed.2025.4917 (2025).
Shi, M. et al. Accelerating discovery of cancer causes for prevention in the era of rising early-onset cancers. Cell 189, 2232–2253 https://doi.org/10.1016/j.cell.2026.03.019 (2026).
Ugai, T. et al. Is early-onset cancer an emerging global epidemic? Current evidence and future implications. Nat. Rev. Clin. Oncol. 19, 656–673 https://doi.org/10.1038/s41571-022-00672-8 (2022).
Giaquinto, A. N. et al. Breast cancer statistics 2024. CA Cancer J. Clin. 74, 477–495 https://doi.org/10.3322/caac.21863 (2024).
Caswell-Jin, J. L. et al. Analysis of breast cancer mortality in the US-1975 to 2019. JAMA 331, 233–241 https://doi.org/10.1001/jama.2023.25881 (2024).
Hendrick, R. E., Helvie, M. A. & Monticciolo, D. L. Breast cancer mortality rates have stopped declining in U.S. women younger than 40 years. Radiology 299, 143–149 https://doi.org/10.1148/radiol.2021203476 (2021).
Siegel, R. L., Kratzer, T. B., Giaquinto, A. N., Sung, H. & Jemal, A. Cancer statistics, 2025. CA Cancer J. Clin. 75, 10–45 https://doi.org/10.3322/caac.21871 (2025).
Gu, H. et al. Global burden and trends of breast cancer: GLOBOCAN 2022 estimates of incidence and mortality in 185 countries. Chin. Med. J. 139, 404–414 https://doi.org/10.1097/CM9.0000000000003921 (2026).
Sharma, R. Global, regional, national burden of breast cancer in 185 countries: evidence from GLOBOCAN 2018. Breast Cancer Res. Treat. 187, 557–567 https://doi.org/10.1007/s10549-020-06083-6 (2021).
National Cancer Institute. SEER*Explorer: An interactive website for SEER cancer statistics https://seer.cancer.gov/statistics-network/explorer/ (2026).
Sopik, V. International variation in breast cancer incidence and mortality in young women. Breast Cancer Res. Treat. 186, 497–507 https://doi.org/10.1007/s10549-020-06003-8 (2021).
Girardi, F. et al. Global breast cancer survival estimates in 2017-2021 to advance the WHO Global Breast Cancer Initiative. Nat. Med. 32, 3313–3321 https://doi.org/10.1038/s41591-026-04531-2 (2026).
Hoskins, K. F. et al. Association of social determinants and tumor biology with racial disparity in survival from early-stage, hormone-dependent breast cancer. JAMA Oncol. 9, 536–545 https://doi.org/10.1001/jamaoncol.2022.7705 (2023).
Hoskins, K. F., Danciu, O. C., Ko, N. Y. & Calip, G. S. Association of race/ethnicity and the 21-gene recurrence score with breast cancer-specific mortality among US women. JAMA Oncol. 7, 370–378 https://doi.org/10.1001/jamaoncol.2020.7320 (2021).
Giaquinto, A. N. et al. Breast cancer statistics, 2022. CA Cancer J. Clin. 72, 524–541 https://doi.org/10.3322/caac.21754 (2022).
Thorn, G. J. et al. The clinical and molecular landscape of breast cancer in women of African and South Asian ancestry. Nat. Commun. 16, 4237 https://doi.org/10.1038/s41467-025-59144-z (2025).
Abdou, Y. et al. Prognostic and predictive insights from genomic assays for breast cancer in diverse populations: a review. JAMA Oncol. 11, 655–663 https://doi.org/10.1001/jamaoncol.2025.0178 (2025).
Howlader, N. et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J. Natl Cancer Inst. 106, dju055 https://doi.org/10.1093/jnci/dju055 (2014).
Vrancken Peeters, N. et al. Five-year conditional relative survival up to 10 years post-diagnosis among adolescent and young adult breast cancer patients by age, stage, and receptor subtype. J. Natl Cancer Cent. 5, 297–305 https://doi.org/10.1016/j.jncc.2025.01.005 (2025).
Khongthong, P., Prateepchaiboon, T. & Ruangsuwan, T. Overall survival and prognostic factors in young women with breast cancer: a retrospective cohort study from Southern Thailand. World J. Surg. Oncol. 24, 229 https://doi.org/10.1186/s12957-026-04349-9 (2026).
Thomas, A. et al. Incidence and survival by human epidermal growth factor receptor 2 status in young women with stage I-III breast cancer: SEER, 2010-2016. Clin. Breast Cancer 20, e410–e422 https://doi.org/10.1016/j.clbc.2020.01.014 (2020).
Avila, J. et al. Stage IV breast cancer incidence and survival, 2010-2021. JAMA Netw. Open 9, e2612042 https://doi.org/10.1001/jamanetworkopen.2026.12042 (2026).
El Saghir, N. S. et al. Improved survival of young patients with breast cancer 40 years and younger at diagnosis. JCO Glob. Oncol. 9, e2200354 https://doi.org/10.1200/GO.22.00354 (2023).
Mallet, A. et al. Real-world evidence of the management and prognosis of young women (⩽40 years) with de novo metastatic breast cancer. Ther. Adv. Med. Oncol. 14, 17588359211070362 https://doi.org/10.1177/17588359211070362 (2022).
Svanoe, A. A. et al. Age-related phenotypes in breast cancer: a population-based study. Int. J. Cancer 154, 2014–2024 https://doi.org/10.1002/ijc.34863 (2024).
Easton, D. F. et al. Gene-panel sequencing and the prediction of breast-cancer risk. N. Engl. J. Med. 372, 2243–2257 https://doi.org/10.1056/NEJMsr1501341 (2015).
Kuchenbaecker, K. B. et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317, 2402–2416 https://doi.org/10.1001/jama.2017.7112 (2017).
Breast Cancer Association Consortium et al. Breast cancer risk genes — association analysis in more than 113,000 women. N. Engl. J. Med. 384, 428–439 https://doi.org/10.1056/NEJMoa1913948 (2021).
Heeke, A. L. et al. The genomic landscape of breast cancer in young and older women. Clin. Breast Cancer 24, 630–638.e3 https://doi.org/10.1016/j.clbc.2024.07.008 (2024).
Apostolou, P. et al. Genetic testing of breast cancer patients with very early-onset breast cancer (≤30 years) yields a high rate of germline pathogenic variants, mainly in the BRCA1, TP53, and BRCA2 genes. Cancers 16, 2368 https://doi.org/10.3390/cancers16132368 (2024).
Evans, D. G. et al. High likelihood of actionable pathogenic variant detection in breast cancer genes in women with very early onset breast cancer. J. Med. Genet. 59, 115–121 https://doi.org/10.1136/jmedgenet-2020-107347 (2022).
Daly, M. B. et al. The association between age at breast cancer diagnosis and prevalence of pathogenic variants. Breast Cancer Res. Treat. 199, 617–626 https://doi.org/10.1007/s10549-023-06946-8 (2023).
Breast Cancer Association Consortium et al. Pathology of tumors associated with pathogenic germline variants in 9 breast cancer susceptibility genes. JAMA Oncol. 8, e216744 https://doi.org/10.1001/jamaoncol.2021.6744 (2022).
Lalloo, F. et al. BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. Eur. J. Cancer 42, 1143–1150 https://doi.org/10.1016/j.ejca.2005.11.032 (2006).
Waks, A. G. et al. Somatic and germline genomic alterations in very young women with breast cancer. Clin. Cancer Res. 28, 2339–2348 https://doi.org/10.1158/1078-0432.CCR-21-2572 (2022).
Isiklar, A. D., Aliyeva, L., Yesilyurt, A., Soyder, A. & Basaran, G. Frequency of germline pathogenic variants in breast cancer predisposition genes among young Turkish breast cancer patients. Breast Cancer Res. Treat. 202, 297–304 https://doi.org/10.1007/s10549-023-07074-z (2023).
de Andrade, K. C. et al. Cancer incidence, patterns, and genotype-phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study. Lancet Oncol. 22, 1787–1798 https://doi.org/10.1016/S1470-2045(21)00580-5 (2021).
Yang, X. et al. Cancer risks associated with germline PALB2 pathogenic variants: an international study of 524 families. J. Clin. Oncol. 38, 674–685 https://doi.org/10.1200/JCO.19.01907 (2020).
Hu, C. et al. A population-based study of genes previously implicated in breast cancer. N. Engl. J. Med. 384, 440–451 https://doi.org/10.1056/NEJMoa2005936 (2021).
Zang, F. et al. Prevalence of BRCA1 and BRCA2 pathogenic variants in 8627 unselected patients with breast cancer: stratification of age at diagnosis, family history and molecular subtype. Breast Cancer Res. Treat. 195, 431–439 https://doi.org/10.1007/s10549-022-06702-4 (2022).
Papadopoulou, E. et al. Germline genetic testing in breast and gynecologic cancers: evaluating age at diagnosis as a determinant. Cancers 18, 1541 https://doi.org/10.3390/cancers18101541 (2026).
Momozawa, Y. et al. Germline pathogenic variants of 11 breast cancer genes in 7,051 Japanese patients and 11,241 controls. Nat. Commun. 9, 4083 https://doi.org/10.1038/s41467-018-06581-8 (2018).
Kratz, C. P. et al. Urgent need to recognize that disease-causing TP53 variants with atypical penetrance require distinct clinical recommendations. J. Natl Cancer Inst. https://doi.org/10.1093/jnci/djag015 (2026).
Tischkowitz, M. et al. Management of individuals with germline variants in PALB2: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet. Med. 23, 1416–1423 https://doi.org/10.1038/s41436-021-01151-8 (2021).
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate (National Comprehensive Cancer Network, 2026).
Pal, T. et al. Consideration of inherited cancer risk on a continuum: an international and multidisciplinary perspective: a points to consider statement of the American College of Medical Genetics and Genomics (ACMG). Genet. Med. 28, 101659 https://doi.org/10.1016/j.gim.2025.101659 (2026).
Metcalfe, K. et al. Frequency of germline pathogenic variants in breast cancer predisposing genes in a national cohort of young women with breast cancer. Br. J. Cancer 135, 917–923 https://doi.org/10.1038/s41416-026-03502-1 (2026).
Schmidt, M. K. et al. Age- and tumor subtype-specific breast cancer risk estimates for CHEK2*1100delC carriers. J. Clin. Oncol. 34, 2750–2760 https://doi.org/10.1200/jco.2016.66.5844 (2016).
Thomas, C. E. & Peters, U. Genomic landscape of cancer in racially and ethnically diverse populations. Nat. Rev. Genet. 26, 336–349 https://doi.org/10.1038/s41576-024-00796-w (2025).
Mortimer, J. E. et al. Prevalence of BRCA1 and BRCA2 variants in an unselected population of women with breast cancer. JAMA Netw. Open 8, e2531577 https://doi.org/10.1001/jamanetworkopen.2025.31577 (2025).
Yap, Y. S. et al. Insights into breast cancer in the east vs the west: a review. JAMA Oncol. 5, 1489–1496 https://doi.org/10.1001/jamaoncol.2019.0620 (2019).
Fergus, K. B. et al. Germline pathogenic variants among women without a history of breast cancer: a secondary analysis of the WISDOM randomized clinical trial. JAMA Intern. Med. https://doi.org/10.1001/jamainternmed.2025.7323 (2025).
Domchek, S. M. et al. Comparison of the prevalence of pathogenic variants in cancer susceptibility genes in Black women and non-hispanic white women with breast cancer in the United States. JAMA Oncol. 7, 1045–1050 https://doi.org/10.1001/jamaoncol.2021.1492 (2021).
Palmer, J. R. et al. Contribution of germline predisposition gene mutations to breast cancer risk in African American women. J. Natl Cancer Inst. 112, 1213–1221 https://doi.org/10.1093/jnci/djaa040 (2020).
Abul-Husn, N. S. et al. Exome sequencing reveals a high prevalence of BRCA1 and BRCA2 founder variants in a diverse population-based biobank. Genome Med. 12, 2 https://doi.org/10.1186/s13073-019-0691-1 (2019).
Amin, S. et al. Frequency and spectrum of BRCA pathogenic/likely pathogenic variants in the Hispanic population of South Florida: a retrospective analysis. J. Clin. Oncol. 43, 10579–10579 https://doi.org/10.1200/JCO.2025.43.16_suppl.10579 (2025).
Yadav, S. et al. Racial and ethnic differences in multigene hereditary cancer panel test results for women with breast cancer. J. Natl Cancer Inst. 113, 1429–1433 https://doi.org/10.1093/jnci/djaa167 (2021).
Lieberman, S. et al. Common founder BRCA2 pathogenic variants and breast cancer characteristics in Ethiopian Jews. Breast Cancer Res. Treat. 193, 217–224 https://doi.org/10.1007/s10549-022-06557-9 (2022).
Ludman, M. D., Philipsborn, S. L., Hartmajer, S., Shwartzman, N. S. & Reinstein, E. Recurring pathogenic variants in the BRCA2 gene in the Ethiopian Jewish population. Founder mutations? Fam. Cancer 21, 121–123 https://doi.org/10.1007/s10689-021-00255-z (2022).
Friebel, T. M. et al. BRCA1 and BRCA2 pathogenic sequence variants in women of African origin or ancestry. Hum. Mutat. 40, 1781–1796 https://doi.org/10.1002/humu.23804 (2019).
Rebbeck, T. R. et al. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum. Mutat. 39, 593–620 https://doi.org/10.1002/humu.23406 (2018).
Nguyen, T. et al. Equity in cancer genomics in the UK: a cross-sectional analysis of a national cancer cohort. Lancet Oncol. 26, 971–980 https://doi.org/10.1016/S1470-2045(25)00199-8 (2025).
Lao, O. et al. Correlation between genetic and geographic structure in Europe. Curr. Biol. 18, 1241–1248 https://doi.org/10.1016/j.cub.2008.07.049 (2008).
Tian, C. et al. Analysis and application of European genetic substructure using 300 K SNP information. PLoS Genet. 4, e4 https://doi.org/10.1371/journal.pgen.0040004 (2008).
Seldin, M. F. et al. European population substructure: clustering of northern and southern populations. PLoS Genet. 2, e143 https://doi.org/10.1371/journal.pgen.0020143 (2006).
HUGO Pan-Asian SNP Consortium et al. Mapping human genetic diversity in Asia. Science 326, 1541–1545 https://doi.org/10.1126/science.1177074 (2009).
Anders, C. K. et al. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J. Clin. Oncol. 26, 3324–3330 https://doi.org/10.1200/JCO.2007.14.2471 (2008).
Plichta, J. K. et al. Breast cancer tumor histopathology, stage at presentation, and treatment in the extremes of age. Breast Cancer Res. Treat. 180, 227–235 https://doi.org/10.1007/s10549-020-05542-4 (2020).
Davis Lynn, B. C. et al. Breast cancer incidence rates in Ghanaian and US Black women from 2013 through 2015. JAMA Netw. Open 8, e2537160 https://doi.org/10.1001/jamanetworkopen.2025.37160 (2025).
US Preventive Services Task Force et al. Screening for breast cancer: US Preventive Services Task Force Recommendation Statement. JAMA 331, 1918–1930 https://doi.org/10.1001/jama.2024.5534 (2024).
American Cancer Society. Breast Cancer Facts & Figures 2024–2025 (American Cancer Society, 2024).
Cho, B. et al. Evaluation of racial/ethnic differences in treatment and mortality among women with triple-negative breast cancer. JAMA Oncol. 7, 1016–1023 https://doi.org/10.1001/jamaoncol.2021.1254 (2021).
Newman, L. Oncologic anthropology: global variations in breast cancer risk, biology, and outcome. J. Surg. Oncol. 128, 959–966 https://doi.org/10.1002/jso.27459 (2023).
Chauvin, P., Huet, T., Gligorov, J. & Sargent, C. Social disparities in the frequency and severity of triple-negative breast cancer at diagnosis in a university hospital in Paris, France: confronting race and ethnic blindness. PLoS ONE 21, e0349041 https://doi.org/10.1371/journal.pone.0349041 (2026).
Arora, K. et al. Genetic ancestry-based differences in biomarker-based eligibility for precision oncology therapies. JAMA Oncol. 11, 310–316 https://doi.org/10.1001/jamaoncol.2024.5794 (2025).
Davis, M. B. & Martini, R. Precision oncology and genetic ancestry: the science behind population-based cancer disparities. Cancer Cell 43, 619–622 https://doi.org/10.1016/j.ccell.2025.03.022 (2025).
Garcia-Cardenas, J. M. et al. Toward equitable precision oncology: monitoring racial and ethnic inclusion in genomics and clinical trials. JCO Precis. Oncol. 8, e2300398 https://doi.org/10.1200/PO.23.00398 (2024).
Telonis, A. G., Rodriguez, D. A., Spanheimer, P. M., Figueroa, M. E. & Goel, N. Genetic ancestry-specific molecular and survival differences in admixed patients with breast cancer. Ann. Surg. 279, 866–873 https://doi.org/10.1097/SLA.0000000000006135 (2024).
Goel, N. et al. Translational epidemiology: an integrative approach to determine the interplay between genetic ancestry and neighborhood socioeconomic status on triple negative breast cancer. Ann. Surg. 276, 430–440 https://doi.org/10.1097/SLA.0000000000005554 (2022).
Chatzipanagiotou, O. P. et al. Genetic ancestry and colorectal cancer in the All of Us dataset. JAMA Netw. Open 9, e2628789 https://doi.org/10.1001/jamanetworkopen.2026.28789 (2026).
Tolentino-Rodriguez, L. et al. Breast cancer characteristics in low- and middle-income countries: an umbrella review. Cancer Epidemiol. 96, 102797 https://doi.org/10.1016/j.canep.2025.102797 (2025).
Torres, D. et al. Interaction between genetic ancestry and common breast cancer susceptibility variants in Colombian women. Int. J. Cancer 144, 2181–2191 https://doi.org/10.1002/ijc.32023 (2019).
Slattery, M. L. et al. Genetic variation in genes involved in hormones, inflammation and energetic factors and breast cancer risk in an admixed population. Carcinogenesis 33, 1512–1521 https://doi.org/10.1093/carcin/bgs163 (2012).
Churpek, J. E. et al. Inherited predisposition to breast cancer among African American women. Breast Cancer Res. Treat. 149, 31–39 https://doi.org/10.1007/s10549-014-3195-0 (2015).
Manirakiza, A. V. C., Mutesa, L., Mathew, C. G. & Olopade, O. I. Breast cancer: genetic risk assessment, diagnostics, and therapeutics in African populations. Annu. Rev. Genomics Hum. Genet. 26, 245–259 https://doi.org/10.1146/annurev-genom-111522-013953 (2025).
Jiagge, E. et al. Comparative analysis of breast cancer phenotypes in African American, White American, and West versus East African patients: correlation between African ancestry and triple-negative breast cancer. Ann. Surg. Oncol. 23, 3843–3849 https://doi.org/10.1245/s10434-016-5420-z (2016).
Paixao, D. et al. Characterization of genetic predisposition to molecular subtypes of breast cancer in Brazilian patients. Front. Oncol. 12, 976959 https://doi.org/10.3389/fonc.2022.976959 (2022).
Miyashita, M. et al. Molecular profiling of a real-world breast cancer cohort with genetically inferred ancestries reveals actionable tumor biology differences between European ancestry and African ancestry patient populations. Breast Cancer Res. 25, 58 https://doi.org/10.1186/s13058-023-01627-2 (2023).
Jia, G. et al. Refining breast cancer genetic risk and biology through multi-ancestry fine-mapping analyses of 192 risk regions. Nat. Genet. 57, 80–87 https://doi.org/10.1038/s41588-024-02031-y (2025).
Jia, G. et al. Genome-wide association analyses of breast cancer in women of African ancestry identify new susceptibility loci and improve risk prediction. Nat. Genet. 56, 819–826 https://doi.org/10.1038/s41588-024-01736-4 (2024).
Hughes, E. et al. Development and validation of a breast cancer polygenic risk score on the basis of genetic ancestry composition. JCO Precis. Oncol. 6, e2200084 https://doi.org/10.1200/PO.22.00084 (2022).
Ping, J. et al. Using genome and transcriptome data from African-ancestry female participants to identify putative breast cancer susceptibility genes. Nat. Commun. 15, 3718 https://doi.org/10.1038/s41467-024-47650-5 (2024).
Li, J. L. et al. Improved polygenic risk prediction models for breast cancer subtypes in women of African ancestry. Nat. Genet. 58, 560–569 https://doi.org/10.1038/s41588-026-02501-5 (2026).
Sun, Y. et al. Polygenic risk scores for breast cancer among African American women with high risk. JAMA Netw. Open 9, e2619285 https://doi.org/10.1001/jamanetworkopen.2026.19285 (2026).
Franco, I. et al. Genomic characterization of aggressive breast cancer in younger women. Ann. Surg. Oncol. 30, 7569–7578 https://doi.org/10.1245/s10434-023-14080-4 (2023).
Scott, L. C., Mobley, L. R., Kuo, T. M. & Il’yasova, D. Update on triple-negative breast cancer disparities for the United States: a population-based study from the United States Cancer Statistics database, 2010 through 2014. Cancer 125, 3412–3417 https://doi.org/10.1002/cncr.32207 (2019).
Dietze, E. C., Sistrunk, C., Miranda-Carboni, G., O’Regan, R. & Seewaldt, V. L. Triple-negative breast cancer in African-American women: disparities versus biology. Nat. Rev. Cancer 15, 248–254 https://doi.org/10.1038/nrc3896 (2015).
Ein Gal, S., Mathis, S., Pathak, B. & Frenkel, M. The role of integrative oncology in patients affected by triple negative breast cancer. Curr. Oncol. Rep. 27, 1144–1154 https://doi.org/10.1007/s11912-025-01711-0 (2025).
Newman, L. A. et al. Hereditary susceptibility for triple negative breast cancer associated with western sub-Saharan African ancestry: results from an international surgical breast cancer collaborative. Ann. Surg. 270, 484–492 https://doi.org/10.1097/SLA.0000000000003459 (2019).
Loibl, S., Poortmans, P., Morrow, M., Denkert, C. & Curigliano, G. Breast cancer. Lancet 397, 1750–1769 https://doi.org/10.1016/S0140-6736(20)32381-3 (2021).
Sanchez-Covarrubias, A. P. et al. Reproductive risk factor patterns in Caribbean women with breast cancer across 4 generations. JAMA Netw. Open 7, e2438091 https://doi.org/10.1001/jamanetworkopen.2024.38091 (2024).
Song, Z. et al. Association of reproductive and menstrual factors with the risk of breast cancer in women: a population-based study. BMC Cancer 25, 1621 https://doi.org/10.1186/s12885-025-15048-1 (2025).
Morch, L. S. et al. Contemporary hormonal contraception and the risk of breast cancer. N. Engl. J. Med. 377, 2228–2239 https://doi.org/10.1056/NEJMoa1700732 (2017).
Hadizadeh, F., Koteci, A., Karlsson, T., Ek, W. E. & Johansson, A. Hormonal contraceptive formulations and breast cancer risk in adolescents and premenopausal women. JAMA Oncol. 11, 1497–1506 https://doi.org/10.1001/jamaoncol.2025.4480 (2025).
Gompel, A. & Simcock, R. Menopausal hormone treatment and breast cancer. Lancet Diabetes Endocrinol. 14, 259–274 https://doi.org/10.1016/S2213-8587(25)00394-8 (2026).
McDonald, J. A. et al. Pregnancy-related factors and breast cancer risk for women across a range of familial risk. JAMA Netw. Open 7, e2427441 https://doi.org/10.1001/jamanetworkopen.2024.27441 (2024).
Anderson, K. N., Schwab, R. B. & Martinez, M. E. Reproductive risk factors and breast cancer subtypes: a review of the literature. Breast Cancer Res. Treat. 144, 1–10 https://doi.org/10.1007/s10549-014-2852-7 (2014).
Nichols, H. B. et al. Breast cancer risk after recent childbirth: a pooled analysis of 15 prospective studies. Ann. Intern. Med. 170, 22–30 https://doi.org/10.7326/M18-1323 (2019).
Islami, F. et al. Breastfeeding and breast cancer risk by receptor status — a systematic review and meta-analysis. Ann. Oncol. 26, 2398–2407 https://doi.org/10.1093/annonc/mdv379 (2015).
Ma, H. et al. Reproductive factors and the risk of triple-negative breast cancer in white women and African-American women: a pooled analysis. Breast Cancer Res. 19, 6 https://doi.org/10.1186/s13058-016-0799-9 (2017).
Virassamy, B. et al. Parity and lactation induce T-cell-mediated breast cancer protection. Nature 649, 449–459 https://doi.org/10.1038/s41586-025-09713-5 (2026).
Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 347, 1713–1727 https://doi.org/10.1016/s0140-6736(96)90806-5 (1996).
Ferguson, D., Fraker, J., Sahni, S., Vegunta, S. & David, P. S. Breast cancer risk in peri- and postmenopausal women with a history of hormonal contraceptive use: a narrative review. Maturitas 208, 108898 https://doi.org/10.1016/j.maturitas.2026.108898 (2026).
Rezoug, Z. et al. Universal genetic testing for newly diagnosed invasive breast cancer. JAMA Netw. Open 7, e2431427 https://doi.org/10.1001/jamanetworkopen.2024.31427 (2024).
Yadav, S. et al. Landscape of somatic genetic alterations and PAM50 intrinsic subtypes in breast cancer associated with germline pathogenic variants in DNA-repair genes. J. Natl Cancer Inst. https://doi.org/10.1093/jnci/djag070 (2026).
Villarreal-Garza, C. et al. Breast cancer in young women in Latin America: an unmet, growing burden. Oncologist 18, 1298–1306 https://doi.org/10.1634/theoncologist.2013-0321 (2013).
Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 https://doi.org/10.3322/caac.21660 (2021).
Effiong, M. E. et al. Age-specific patterns of breast cancer in Nigerian women unraveled through histological analysis. Sci. Rep. 16, 128 https://doi.org/10.1038/s41598-025-28685-0 (2025).
Williams, L. A., Olshan, A. F., Tse, C. K., Bell, M. E. & Troester, M. A. Alcohol intake and invasive breast cancer risk by molecular subtype and race in the Carolina Breast Cancer Study. Cancer Causes Control. 27, 259–269 https://doi.org/10.1007/s10552-015-0703-4 (2016).
Sudan, S. K. et al. Obesity and early-onset breast cancer and specific molecular subtype diagnosis in Black and white women: NIMHD Social Epigenomics Program. JAMA Netw. Open 7, e2421846 https://doi.org/10.1001/jamanetworkopen.2024.21846 (2024).
Williams, L. A. et al. Alcohol intake and breast cancer risk in African American women from the AMBER Consortium. Cancer Epidemiol. Biomarkers Prev. 26, 787–794 https://doi.org/10.1158/1055-9965.EPI-16-0792 (2017).
Premenopausal Breast Cancer Collaborative Group et al. Association of body mass index and age with subsequent breast cancer risk in premenopausal women. JAMA Oncol. 4, e181771 https://doi.org/10.1001/jamaoncol.2018.1771 (2018).
van den Brandt, P. A. et al. Body size and weight change over adulthood and risk of breast cancer by menopausal and hormone receptor status: a pooled analysis of 20 prospective cohort studies. Eur. J. Epidemiol. 36, 37–55 https://doi.org/10.1007/s10654-020-00688-3 (2021).
Fang, Z. & Giovannucci, E. L. The timing of adiposity and changes in the life course on the risk of cancer. Cancer Metastasis Rev. 41, 471–489 https://doi.org/10.1007/s10555-022-10054-2 (2022).
Sohi, I. et al. Alcoholic beverage consumption and female breast cancer risk: a systematic review and meta-analysis of prospective cohort studies. Alcohol. Clin. Exp. Res. 48, 2222–2241 https://doi.org/10.1111/acer.15493 (2024).
Morford, K. L., Tetrault, J. M. & O’Connor, P. G. Alcohol and cancer risk. JAMA 334, 908–909 https://doi.org/10.1001/jama.2025.11229 (2025).
Chen, W. Y., Rosner, B., Hankinson, S. E., Colditz, G. A. & Willett, W. C. Moderate alcohol consumption during adult life, drinking patterns, and breast cancer risk. JAMA 306, 1884–1890 https://doi.org/10.1001/jama.2011.1590 (2011).
Timmins, I. R. et al. International pooled analysis of leisure-time physical activity and premenopausal breast cancer in women from 19 cohorts. J. Clin. Oncol. 42, 927–939 https://doi.org/10.1200/JCO.23.01101 (2024).
Parrish, M., Traugh, N., Seraj, M. & Kuperwasser, C. Field cancerization, accelerated aging, and immunosuppression: the rapid rise of hormone-sensitive and early-onset breast cancer. NPJ Breast Cancer 11, 128 https://doi.org/10.1038/s41523-025-00840-w (2025).
Zeinomar, N., Oskar, S., Kehm, R. D., Sahebzeda, S. & Terry, M. B. Environmental exposures and breast cancer risk in the context of underlying susceptibility: a systematic review of the epidemiological literature. Env. Res. 187, 109346 https://doi.org/10.1016/j.envres.2020.109346 (2020).
Terry, M. B. et al. Environmental exposures during windows of susceptibility for breast cancer: a framework for prevention research. Breast Cancer Res. 21, 96 https://doi.org/10.1186/s13058-019-1168-2 (2019).
Ekenga, C. C., Parks, C. G. & Sandler, D. P. Chemical exposures in the workplace and breast cancer risk: a prospective cohort study. Int. J. Cancer 137, 1765–1774 https://doi.org/10.1002/ijc.29545 (2015).
Le Provost, B. et al. Residential exposure to ambient fine particulate matter (PM2.5) and nitrogen dioxide (NO2) and incident breast cancer among young women in Ontario, Canada. Cancer Epidemiol. 92, 102606 https://doi.org/10.1016/j.canep.2024.102606 (2024).
Gormley, M. et al. A Society-to-Cells approach to evaluating multilevel and interrelated drivers of breast cancer disparities in Black women. NPJ Breast Cancer 11, 90 https://doi.org/10.1038/s41523-025-00812-0 (2025).
Barnard, M. E. et al. Associations between social drivers of health and breast cancer stage at diagnosis among U.S. Black women. NPJ Breast Cancer 11, 85 https://doi.org/10.1038/s41523-025-00804-0 (2025).
Kehm, R. D., Lloyd, S. E., Burke, K. R. & Terry, M. B. Advancing environmental epidemiologic methods to confront the cancer burden. Am. J. Epidemiol. 194, 195–207 https://doi.org/10.1093/aje/kwae175 (2025).
Duboeuf, M. et al. Long-term exposure to air pollution at residential and workplace addresses and breast cancer risk: a case-control study nested in the French E3N-Generations cohort from 1990 to 2011. Eur. J. Cancer 210, 114293 https://doi.org/10.1016/j.ejca.2024.114293 (2024).
Miller, C. A. et al. Cancer prevention in context: interplay of perceived discrimination, neighborhood deprivation, and cancer-related risk and protective factors. J. Natl Cancer Inst. 118, 1715–1723 https://doi.org/10.1093/jnci/djag101 (2026).
Goel, N. et al. Structural racism and breast cancer-specific survival: impact of economic and racial residential segregation. Ann. Surg. 275, 776–783 https://doi.org/10.1097/SLA.0000000000005375 (2022).
Plascak, J. J. & Bauer, C. X. Uptake and utility of geographically sensitive neighborhoodwide association studies of cancer. JAMA Netw. Open 9, e2558191 https://doi.org/10.1001/jamanetworkopen.2025.58191 (2026).
Peiris, M. N. et al. Breast cancer inequities: the intersectional role of social epidemiology and tumor biology. Cancer Causes Control 37, 57 https://doi.org/10.1007/s10552-026-02138-z (2026).
Falcone, M. et al. Impact of structural racism and social determinants of health on disparities in breast cancer mortality. Cancer Res. 84, 3924–3935 https://doi.org/10.1158/0008-5472.CAN-24-1359 (2024).
Coughlin, S. S. Social determinants of breast cancer risk, stage, and survival. Breast Cancer Res. Treat. 177, 537–548 https://doi.org/10.1007/s10549-019-05340-7 (2019).
Goel, N., Hernandez, A. & Cole, S. W. Social genomic determinants of health: understanding the molecular pathways by which neighborhood disadvantage affects cancer outcomes. J. Clin. Oncol. 42, 3618–3627 https://doi.org/10.1200/JCO.23.02780 (2024).
Maas, P. et al. Breast cancer risk from modifiable and nonmodifiable risk factors among white women in the United States. JAMA Oncol. 2, 1295–1302 https://doi.org/10.1001/jamaoncol.2016.1025 (2016).
Tamimi, R. M. et al. Population attributable risk of modifiable and nonmodifiable breast cancer risk factors in postmenopausal breast cancer. Am. J. Epidemiol. 184, 884–893 https://doi.org/10.1093/aje/kww145 (2016).
Britt, K. L., Cuzick, J. & Phillips, K. A. Key steps for effective breast cancer prevention. Nat. Rev. Cancer 20, 417–436 https://doi.org/10.1038/s41568-020-0266-x (2020).
Brown, K. A. Metabolic pathways in obesity-related breast cancer. Nat. Rev. Endocrinol. 17, 350–363 https://doi.org/10.1038/s41574-021-00487-0 (2021).
Naaman, S. C., Shen, S., Zeytinoglu, M. & Iyengar, N. M. Obesity and breast cancer risk: the oncogenic implications of metabolic dysregulation. J. Clin. Endocrinol. Metab. 107, 2154–2166 https://doi.org/10.1210/clinem/dgac241 (2022).
Guo, W., Fensom, G. K., Reeves, G. K. & Key, T. J. Physical activity and breast cancer risk: results from the UK Biobank prospective cohort. Br. J. Cancer 122, 726–732 https://doi.org/10.1038/s41416-019-0700-6 (2020).
Papadimitriou, N. et al. Physical activity and risks of breast and colorectal cancer: a Mendelian randomisation analysis. Nat. Commun. 11, 597 https://doi.org/10.1038/s41467-020-14389-8 (2020).
Kotsopoulos, J. et al. Parity, breastfeeding, and the risk of early-onset breast cancer in women with a BRCA1 pathogenic variant. Br. J. Cancer 133, 104–110 https://doi.org/10.1038/s41416-025-03029-x (2025).
Nelson, H. D. et al. Patient navigation services for breast and cervical cancer screening and follow-up: a meta-analysis. JAMA Intern. Med. 185, 976–985 https://doi.org/10.1001/jamainternmed.2025.1590 (2025).
Qaseem, A. et al. Screening for breast cancer in asymptomatic, average-risk adult females: a guidance statement from the American College of Physicians (version 2). Ann. Intern. Med. https://doi.org/10.7326/ANNALS-25-05116 (2026).
Hu, X. et al. Presentation and characteristics of breast cancer in young women under age 40. Breast Cancer Res. Treat. 186, 209–217 https://doi.org/10.1007/s10549-020-06000-x (2021).
Holt, D. B. Breast density masking and the need for precision screening. JAMA 335, 1385–1386 https://doi.org/10.1001/jama.2026.2443 (2026).
Kim, S. H. et al. Mammographic density as a predictor of invasive breast cancer and ductal carcinoma in situ in over six million South Korean women. Breast Cancer Res. Treat. 211, 341–350 https://doi.org/10.1007/s10549-025-07648-z (2025).
Perera, D. et al. The distribution of breast density in women aged 18 years and older. Breast Cancer Res. Treat. 205, 521–531 https://doi.org/10.1007/s10549-024-07269-y (2024).
Dreher, N. et al. A case-case analysis of women with breast cancer: predictors of interval vs screen-detected cancer. Breast Cancer Res. Treat. 191, 623–629 https://doi.org/10.1007/s10549-021-06451-w (2022).
Zhang, Y. et al. Incidence and risk factors of interval and screen-detected breast cancer. JAMA Oncol. 11, 519–527 https://doi.org/10.1001/jamaoncol.2025.0167 (2025).
Trentham-Dietz, A. et al. Collaborative modeling to compare different breast cancer screening strategies: a decision analysis for the US Preventive Services Task Force. JAMA 331, 1947–1960 https://doi.org/10.1001/jama.2023.24766 (2024).
Kerlikowske, K., Esserman, L. & Tice, J. A. Screening mammography for 40-year-old women-whose decision? JAMA Intern. Med. 184, 1281–1282 https://doi.org/10.1001/jamainternmed.2024.4277 (2024).
Hartmann, L. C., Degnim, A. C., Santen, R. J., Dupont, W. D. & Ghosh, K. Atypical hyperplasia of the breast-risk assessment and management options. N. Engl. J. Med. 372, 78–89 https://doi.org/10.1056/NEJMsr1407164 (2015).
Baker, J. et al. Atypical ductal or lobular hyperplasia, lobular carcinoma in-situ, flat epithelial atypia, and future risk of developing breast cancer: systematic review and meta-analysis. Breast 78, 103807 https://doi.org/10.1016/j.breast.2024.103807 (2024).
Menes, T. S. et al. Subsequent breast cancer risk following diagnosis of atypical ductal hyperplasia on needle biopsy. JAMA Oncol. 3, 36–41 https://doi.org/10.1001/jamaoncol.2016.3022 (2017).
Li, S. et al. Segregation analysis of 17,425 population-based breast cancer families: evidence for genetic susceptibility and risk prediction. Am. J. Hum. Genet. 109, 1777–1788 https://doi.org/10.1016/j.ajhg.2022.09.006 (2022).
Wendt, C. & Margolin, S. Identifying breast cancer susceptibility genes - a review of the genetic background in familial breast cancer. Acta Oncol. 58, 135–146 https://doi.org/10.1080/0284186X.2018.1529428 (2019).
Dossa, F. et al. Breast and ovarian cancer among individuals undergoing BRCA1 and BRCA2 testing. JAMA Netw. Open 9, e2626334 https://doi.org/10.1001/jamanetworkopen.2026.26334 (2026).
Makhnoon, S. et al. Uptake of cancer risk management strategies among women who undergo cascade genetic testing for breast cancer susceptibility genes. Cancer 127, 3605–3613 https://doi.org/10.1002/cncr.33668 (2021).
Botty van den Bruele, A. & Weiss, A. Society of Surgical Oncology Breast Disease Site Work Group. Updated guidelines on when to consider germline testing for patients with breast cancer. Ann. Surg. Oncol. 31, 5479–5482 https://doi.org/10.1245/s10434-024-15638-6 (2024).
Koldehoff, A. et al. Cost-effectiveness of targeted genetic testing for breast and ovarian cancer: a systematic review. Value Health 24, 303–312 https://doi.org/10.1016/j.jval.2020.09.016 (2021).
Berliner, J. L., Cummings, S. A., Boldt Burnett, B. & Ricker, C. N. Risk assessment and genetic counseling for hereditary breast and ovarian cancer syndromes —practice resource of the National Society of Genetic Counselors. J. Genet. Couns. 30, 342–360 https://doi.org/10.1002/jgc4.1374 (2021).
Terry, M. B. et al. 10-year performance of four models of breast cancer risk: a validation study. Lancet Oncol. 20, 504–517 https://doi.org/10.1016/S1470-2045(18)30902-1 (2019).
Pal Choudhury, P. et al. Comparative validation of the BOADICEA and Tyrer-Cuzick breast cancer risk models incorporating classical risk factors and polygenic risk in a population-based prospective cohort of women of European ancestry. Breast Cancer Res. 23, 22 https://doi.org/10.1186/s13058-021-01399-7 (2021).
Aliberti, G. M., Weinstein, A. R. & Schonberg, M. A. When risk scores meet mammography-navigating supplemental screening decisions. JAMA Intern. Med. 186, 927–928 https://doi.org/10.1001/jamainternmed.2026.2420 (2026).
National Comprehensive Cancer Network. Breast Cancer Screening and Diagnosis (NCCN, 2026).
National Comprehensive Cancer Network. Breast Cancer Risk Reduction (NCCN, 2026).
Saslow, D. et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J. Clin. 57, 75–89 https://doi.org/10.3322/canjclin.57.2.75 (2007).
Petitjean, C. et al. Evaluating the performance of the breast and ovarian analysis of disease incidence algorithm model in predicting 10-year breast cancer risks in UK Biobank. J. Natl Cancer Inst. 117, 948–958 https://doi.org/10.1093/jnci/djae335 (2025).
Mavaddat, N. et al. Polygenic risk scores for prediction of breast cancer and breast cancer subtypes. Am. J. Hum. Genet. 104, 21–34 https://doi.org/10.1016/j.ajhg.2018.11.002 (2019).
Yang, X., Kar, S., Antoniou, A. C. & Pharoah, P. D. P. Polygenic scores in cancer. Nat. Rev. Cancer 23, 619–630 https://doi.org/10.1038/s41568-023-00599-x (2023).
Yang, X. et al. Prospective validation of the BOADICEA multifactorial breast cancer risk prediction model in a large prospective cohort study. J. Med. Genet. 59, 1196–1205 https://doi.org/10.1136/jmg-2022-108806 (2022).
Hovhannisyan, M. et al. Population-specific validation and comparison of the performance of 77- and 313-variant polygenic risk scores for breast cancer risk prediction. Cancer 130, 2978–2987 https://doi.org/10.1002/cncr.35337 (2024).
Esserman, L. J. et al. Risk-based vs annual breast cancer screening: the WISDOM randomized clinical trial. JAMA https://doi.org/10.1001/jama.2025.24784 (2025).
Pashayan, N. et al. Personalized early detection and prevention of breast cancer: ENVISION consensus statement. Nat. Rev. Clin. Oncol. 17, 687–705 https://doi.org/10.1038/s41571-020-0388-9 (2020).
Du, Z. et al. Evaluating polygenic risk scores for breast cancer in women of African ancestry. J. Natl Cancer Inst. 113, 1168–1176 https://doi.org/10.1093/jnci/djab050 (2021).
Stutzin Donoso, F. et al. CanRisk-GP protocol: a feasibility study of incorporating proactive multifactorial breast cancer risk assessment into general practice. PLoS ONE 20, e0336902 https://doi.org/10.1371/journal.pone.0336902 (2025).
Hunter, D. J. & Inouye, M. Clinical uses of common genetic variants associated with common diseases. N. Engl. J. Med. 395, 1206–1217 https://doi.org/10.1056/NEJMra2413201 (2026).
Tsoulaki, O. et al. Joint ABS-UKCGG-CanGene-CanVar consensus regarding the use of CanRisk in clinical practice. Br. J. Cancer 130, 2027–2036 https://doi.org/10.1038/s41416-024-02733-4 (2024).
Gu, M., Zhang, W. Z., Fitzgerald, R. C., Frankell, A. M. & Vassiliou, G. S. Harnessing genomics for early cancer detection, risk stratification and prevention. Nat. Genet. 58, 704–716 https://doi.org/10.1038/s41588-026-02505-1 (2026).
Esserman, L. et al. The WISDOM study: a new approach to screening can and should be tested. Breast Cancer Res. Treat. 189, 593–598 https://doi.org/10.1007/s10549-021-06346-w (2021).
Fiscalini, A. et al. WISDOM randomized trial comparing risk-based versus annual breast cancer screening: study cohort characteristics and design. npj Breast Cancer 12, 108 https://doi.org/10.1038/s41523-026-00952-x (2026).
Leggat-Barr, K. et al. Early ascertainment of breast cancer diagnoses comparing self-reported questionnaires and electronic health record data warehouse: the WISDOM Study. JCO Clin. Cancer Inf. 7, e2300019 https://doi.org/10.1200/CCI.23.00019 (2023).
Lubinski, J. et al. MRI surveillance and breast cancer mortality in women with BRCA1 and BRCA2 sequence variations. JAMA Oncol. 10, 493–499 https://doi.org/10.1001/jamaoncol.2023.6944 (2024).
Lee, T. C., Reyna, C., Shaughnessy, E. & Lewis, J. D. Screening of populations at high risk for breast cancer. J. Surg. Oncol. 120, 820–830 https://doi.org/10.1002/jso.25611 (2019).
Whitaker, K. D., Sheth, D. & Olopade, O. I. Dynamic contrast-enhanced magnetic resonance imaging for risk-stratified screening in women with BRCA mutations or high familial risk for breast cancer: are we there yet? Breast Cancer Res. Treat. 183, 243–250 https://doi.org/10.1007/s10549-020-05759-3 (2020).
Bick, U. et al. High-risk breast cancer surveillance with MRI: 10-year experience from the German consortium for hereditary breast and ovarian cancer. Breast Cancer Res. Treat. 175, 217–228 https://doi.org/10.1007/s10549-019-05152-9 (2019).
Expert Panel on Breast Imaging ACR Appropriateness Criteria® female breast cancer screening: 2025 update. J. Am. Coll. Radiol. 22, S508–S530 https://doi.org/10.1016/j.jacr.2025.08.044 (2025).
Cornell, L. F. Comparison of high-risk breast cancer screenings with concurrent versus staggered breast MRI and mammogram schedules. J. Clin. Med. 15, 4239 https://doi.org/10.3390/jcm15114239 (2026).
Cai, Y. et al. A systematic review of recommendations on screening strategies for breast cancer due to hereditary predisposition: who, when, and how. Cancer Med. 10, 3437–3448 https://doi.org/10.1002/cam4.3898 (2021).
Saadatmand, S. et al. MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial. Lancet Oncol. 20, 1136–1147 https://doi.org/10.1016/S1470-2045(19)30275-X (2019).
Tosteson, A. N. A. et al. Outcomes of density-targeted supplemental breast magnetic resonance imaging screening by breast cancer risk: long-term health and economic considerations. Ann. Intern. Med. 179, 486–496 https://doi.org/10.7326/ANNALS-25-00792 (2026).
Miglioretti, D. L. et al. Association between false-positive results and return to screening mammography in the breast cancer surveillance consortium cohort. Ann. Intern. Med. 177, 1297–1307 https://doi.org/10.7326/M24-0123 (2024).
Nelson, H. D. et al. Harms of breast cancer screening: systematic review to update the 2009 U.S. Preventive Services Task Force Recommendation. Ann. Intern. Med. 164, 256–267 https://doi.org/10.7326/M15-0970 (2016).
Qaseem, A. et al. Screening for breast cancer in average-risk women: a guidance statement from the American College of Physicians. Ann. Intern. Med. 170, 547–560 https://doi.org/10.7326/M18-2147 (2019).
Boucheron, P. et al. Measuring the WHO Global Breast Cancer Initiative Pillars’ key performance indicators in sub-Saharan Africa: experience in the African Breast Cancer-Disparities in Outcomes hospital-based cohort study. EClinicalMedicine 81, 103104 https://doi.org/10.1016/j.eclinm.2025.103104 (2025).
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, Esophageal, and Gastric (NCCN, 2026).
Esserman, L. J., Study, W. & Athena, I. The WISDOM Study: breaking the deadlock in the breast cancer screening debate. NPJ Breast Cancer 3, 34 https://doi.org/10.1038/s41523-017-0035-5 (2017).
Wang, T. et al. Validation study of risk-reduction activities after personalized breast cancer education tool in the WISDOM study. NPJ Breast Cancer 10, 90 https://doi.org/10.1038/s41523-024-00681-z (2024).
Duggan, C. et al. National health system characteristics, breast cancer stage at diagnosis, and breast cancer mortality: a population-based analysis. Lancet Oncol. 22, 1632–1642 https://doi.org/10.1016/S1470-2045(21)00462-9 (2021).
Agbedinu, K. et al. A scoping review on barriers to cancer diagnosis and care in low- and middle-income countries. Cancer Epidemiol. Biomarkers Prev. 34, 1066–1073 https://doi.org/10.1158/1055-9965.EPI-25-0120 (2025).
Loizidis, S., Stanciu, M. A. & Ignatiadis, M. Liquid biopsy in breast cancer: promises and challenges. Curr. Opin. Oncol. 37, 512–521 https://doi.org/10.1097/CCO.0000000000001168 (2025).
Qiu, P. et al. Advancements in liquid biopsy for breast cancer: molecular biomarkers and clinical applications. Cancer Treat. Rev. 139, 102979 https://doi.org/10.1016/j.ctrv.2025.102979 (2025).
Lin, X. et al. Circulating tumor DNA in breast cancer: from technological foundation to clinical implementation. Cancer Treat. Rev. 144, 103108 https://doi.org/10.1016/j.ctrv.2026.103108 (2026).
Wood, M. E. et al. Performance of multiple multi-cancer detection tests using a large independent reference set (Alliance A212102). J. Natl Cancer Inst. 118, 730–736 https://doi.org/10.1093/jnci/djag001 (2026).
Garcia-Murillas, I. et al. Assessment of molecular relapse detection in early-stage breast cancer. JAMA Oncol. 5, 1473–1478 https://doi.org/10.1001/jamaoncol.2019.1838 (2019).
Sasieni, P. et al. Effect of screening with multicancer early-detection test on late-stage cancer diagnosis. N. Engl. J. Med. 395, 1374–1386 https://doi.org/10.1056/NEJMoa2505723 (2026).
Bermudez-Guzman, L. Signal-to-care gap in multicancer early detection. JAMA Intern. Med. 186, 1193–1194 https://doi.org/10.1001/jamainternmed.2026.2744 (2026).
Snead, C. M., Zheng, D., Ngo-Metzger, Q. & Gould, M. K. Multicancer detection assays: promise and potential harms of a novel cancer screening tool. Perm. J. 30, 1–7 https://doi.org/10.7812/TPP/25.075 (2026).
Schlam, I., Tolaney, S. M., Lin, N. U., Parsons, H. & Morganti, S. Circulating tumor DNA in early breast cancer: a review. JAMA Oncol. 12, 773–784 https://doi.org/10.1001/jamaoncol.2026.1465 (2026).
Smith, R. A., Cokkinides, V. & Brawley, O. W. Cancer screening in the United States, 2008: a review of current American Cancer Society guidelines and cancer screening issues. CA Cancer J. Clin. 58, 161–179 https://doi.org/10.3322/CA.2007.0017 (2008).
Chavez-Yenter, D. et al. Association of disparities in family history and family cancer history in the electronic health record with sex, race, Hispanic or Latino ethnicity, and language preference in 2 large US health care systems. JAMA Netw. Open 5, e2234574 https://doi.org/10.1001/jamanetworkopen.2022.34574 (2022).
Record, S. M. et al. Breast cancer risk assessment and screening practices reported via an online survey. Ann. Surg. Oncol. 30, 6219–6229 https://doi.org/10.1245/s10434-023-13903-8 (2023).
McGarrigle, S. A. et al. Risk prediction models for familial breast cancer. Cochrane Database Syst. Rev. 6, CD013185 https://doi.org/10.1002/14651858.CD013185.pub2 (2026).
Menes, T. S., Sella, T. & Chodick, G. Time to cancer diagnosis in young women presenting to surgeons with breast-related symptoms: a population-based cohort study. J. Womens Health 29, 493–502 https://doi.org/10.1089/jwh.2019.7967 (2020).
Ruddy, K. J. et al. Breast cancer presentation and diagnostic delays in young women. Cancer 120, 20–25 https://doi.org/10.1002/cncr.28287 (2014).
Webber, C., Whitehead, M., Eisen, A., Holloway, C. M. B. & Groome, P. A. Factors associated with waiting time to breast cancer diagnosis among symptomatic breast cancer patients: a population-based study from Ontario, Canada. Breast Cancer Res. Treat. 187, 225–235 https://doi.org/10.1007/s10549-020-06051-0 (2021).
Ulanday, K. T. et al. Cancers missed, women dismissed yet persist: natural language processing of online forums. Breast Cancer Res. 27, 78 https://doi.org/10.1186/s13058-025-01985-z (2025).
Miller, K. D. et al. Cancer statistics for adolescents and young adults, 2020. CA Cancer J. Clin. 70, 443–459 https://doi.org/10.3322/caac.21637 (2020).
Expert Panel on Breast Imaging ACR Appropriateness Criteria® breast imaging during pregnancy. J. Am. Coll. Radiol. 22, S492–S507 https://doi.org/10.1016/j.jacr.2025.08.045 (2025).
Fazeli, S., Sakala, M., Rakow-Penner, R. & Ojeda-Fournier, H. Cancer in pregnancy: breast cancer. Abdom. Radiol. 48, 1645–1662 https://doi.org/10.1007/s00261-023-03824-1 (2023).
Harbeck, N. et al. Breast cancer. Nat. Rev. Dis. Primers 5, 66 https://doi.org/10.1038/s41572-019-0111-2 (2019).
Ribeiro, R. et al. Guidelines of the Brazilian Society of Surgical Oncology for anatomopathological, immunohistochemical, and molecular testing in female tumors. J. Surg. Oncol. 130, 882–895 https://doi.org/10.1002/jso.27717 (2024).
Allison, K. H. et al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP Guideline Update. J. Clin. Oncol. 38, 1346–1366 https://doi.org/10.1200/JCO.19.02309 (2020).
Reissis, Y., Miller, B., Friebel, R. & Hargest, R. Where do delays occur? A systematic review of the barriers to early breast cancer diagnosis across South Africa’s health system. BMJ Open 16, e122056 https://doi.org/10.1136/bmjopen-2026-122056 (2026).
Ngwa, W. et al. Cancer in sub-Saharan Africa: a Lancet Oncology Commission. Lancet Oncol. 23, e251–e312 https://doi.org/10.1016/S1470-2045(21)00720-8 (2022).
Anderson, B. O., Duggan, C. & Scheel, J. R. Resource-appropriate evidence-based strategies to improve breast cancer outcomes in low- and middle-income countries guided by the Breast Health Global Initiative and Global Breast Cancer Initiative. J. Surg. Oncol. 128, 952–958 https://doi.org/10.1002/jso.27480 (2023).
Distelhorst, S. R. et al. Optimisation of the continuum of supportive and palliative care for patients with breast cancer in low-income and middle-income countries: executive summary of the Breast Health Global Initiative, 2014. Lancet Oncol. 16, e137–e147 https://doi.org/10.1016/S1470-2045(14)70457-7 (2015).
Ong, S. K. et al. Feasibility of monitoring Global Breast Cancer Initiative Framework key performance indicators in 21 Asian National Cancer Centers Alliance member countries. EClinicalMedicine 67, 102365 https://doi.org/10.1016/j.eclinm.2023.102365 (2024).
Ntekim, A. et al. Pragmatic clinical trial assessing response to neoadjuvant docetaxel and trastuzumab in Nigerian women with human epidermal growth factor receptor 2-positive breast cancer. JCO Glob. Oncol. 12, e2500287 https://doi.org/10.1200/GO-25-00287 (2026).
Buzdar, A. U. et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J. Clin. Oncol. 23, 3676–3685 https://doi.org/10.1200/JCO.2005.07.032 (2005).
Buzdar, A. U. et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin. Cancer Res. 13, 228–233 https://doi.org/10.1158/1078-0432.CCR-06-1345 (2007).
Meernik, C. et al. Material and psychological financial hardship related to employment disruption among female adolescent and young adult cancer survivors. Cancer 127, 137–148 https://doi.org/10.1002/cncr.33190 (2021).
Tangka, F. K. L. et al. Insurance coverage, employment status, and financial well-being of young women diagnosed with breast cancer. Cancer Epidemiol. Biomarkers Prev. 29, 616–624 https://doi.org/10.1158/1055-9965.EPI-19-0352 (2020).
Myers, S. P. et al. Financial difficulty over time in young adults with breast cancer. JAMA Netw. Open 7, e2446091 https://doi.org/10.1001/jamanetworkopen.2024.46091 (2024).
Di Giuseppe, G., Jetha, A., Pechlivanoglou, P. & Pole, J. D. Long-term dynamic financial impacts among adolescents and young adults with cancer: a longitudinal matched-cohort study. J. Clin. Oncol. 43, 2467–2478 https://doi.org/10.1200/JCO-24-02121 (2025).
Guzauskas, G. F. et al. Population genomic screening for three common hereditary conditions: a cost-effectiveness analysis. Ann. Intern. Med. 176, 585–595 https://doi.org/10.7326/M22-0846 (2023).
Guo, F. et al. Cost-effectiveness of population-based multigene testing for breast and ovarian cancer prevention. JAMA Netw. Open 7, e2356078 https://doi.org/10.1001/jamanetworkopen.2023.56078 (2024).
Myers, S. P. et al. Impact of age and treatment-related adverse events on financial toxicity among patients with breast cancer: a systematic review. J. Cancer Surviv. https://doi.org/10.1007/s11764-025-01881-7 (2025).
Myers, S. P. et al. Treatment-related adverse events as a source of financial hardship in young adults with breast cancer: a qualitative study. Support. Care Cancer 33, 884 https://doi.org/10.1007/s00520-025-09887-8 (2025).
Cherny, N. I. et al. ESMO Global Consortium Study on the availability, out-of-pocket costs, and accessibility of cancer medicines: 2023 update. Ann. Oncol. 36, 247–262 https://doi.org/10.1016/j.annonc.2024.12.005 (2025).
Trapani, D. & Murthy, S. S. Progress in global breast cancer control. Curr. Opin. Oncol. 37, 529–533 https://doi.org/10.1097/CCO.0000000000001163 (2025).
Barrios, C. et al. Barriers in access to oncology drugs - a global crisis. Nat. Rev. Clin. Oncol. 20, 7–15 https://doi.org/10.1038/s41571-022-00700-7 (2023).
Wilson, B. E. et al. Global cancer drug development — a report from the 2022 Accelerating Anticancer Agent Development and Validation Meeting. JCO Glob. Oncol. https://doi.org/10.1200/go.23.00294 (2023).
Erfani, P. et al. Advancing global pharmacoequity in oncology. JAMA Oncol. 11, 55–59 https://doi.org/10.1001/jamaoncol.2024.5032 (2025).
Cavaleri, M. et al. A roadmap for fostering timely regulatory and ethics approvals of international clinical trials in support of global health research systems. Lancet Glob. Health 13, e769–e777 https://doi.org/10.1016/S2214-109X(24)00515-1 (2025).
Hickey, M. et al. Managing menopause after cancer. Lancet 403, 984–996 https://doi.org/10.1016/S0140-6736(23)02802-7 (2024).
Vo, J. B. et al. Long-term cardiovascular disease risk after anthracycline and trastuzumab treatments in US breast cancer survivors. J. Natl Cancer Inst. 116, 1384–1394 https://doi.org/10.1093/jnci/djae107 (2024).
Runowicz, C. D. et al. American Cancer Society/American Society of Clinical Oncology breast cancer survivorship care guideline. J. Clin. Oncol. 34, 611–635 https://doi.org/10.1200/JCO.2015.64.3809 (2016).
Vrancken Peeters, N. et al. Long-term health issues of adolescent and young adult breast cancer survivors. Clin. Breast Cancer 26, 200–207.e4 https://doi.org/10.1016/j.clbc.2025.10.009 (2026).
Rosenberg, S. M. et al. Association of breast cancer surgery with quality of life and psychosocial well-being in young breast cancer survivors. JAMA Surg. 155, 1035–1042 https://doi.org/10.1001/jamasurg.2020.3325 (2020).
Albini, A., DeCensi, A., Cavalli, F. & Costa, A. Cancer prevention and interception: a new era for chemopreventive approaches. Clin. Cancer Res. 22, 4322–4327 https://doi.org/10.1158/1078-0432.CCR-16-0695 (2016).
Grieco, C., Pandya, T. & Swanton, C. Molecular cancer prevention: intercepting disease. Mol. Oncol. https://doi.org/10.1002/1878-0261.70258 (2026).
Blondeaux, E. et al. Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study. Lancet Oncol. 26, 759–770 https://doi.org/10.1016/S1470-2045(25)00152-4 (2025).
US Preventive Services Task Force Medication use to reduce risk of breast cancer: US Preventive Services Task Force recommendation statement. JAMA 322, 857–867 https://doi.org/10.1001/jama.2019.11885 (2019).
Visvanathan, K. et al. Use of endocrine therapy for breast cancer risk reduction: ASCO clinical practice guideline update. J. Clin. Oncol. 37, 3152–3165 https://doi.org/10.1200/JCO.19.01472 (2019).
Nakhlis, F. et al. American Society of Breast Surgeons, Society of Breast Imaging, and College of American Pathology 2026 guidelines for the management of proliferative lesions with atypia and lobular carcinoma in situ. JAMA Surg. 161, 1076–1083 https://doi.org/10.1001/jamasurg.2026.3552 (2026).
Leggat-Barr, K. et al. A roadmap to reduce the incidence and mortality of breast cancer by rethinking our approach to women’s health. Breast Cancer Res. Treat. 209, 1–14 https://doi.org/10.1007/s10549-024-07522-4 (2025).
Frey, M. K. et al. What happens in the long term: uptake of cancer surveillance and prevention strategies among at-risk relatives with pathogenic variants detected via cascade testing. Cancer 128, 4241–4250 https://doi.org/10.1002/cncr.34482 (2022).
Dubsky, P. et al. BRCA genetic testing and counseling in breast cancer: how do we meet our patients’ needs? NPJ Breast Cancer 10, 77 https://doi.org/10.1038/s41523-024-00686-8 (2024).
Wang, Y., Malkin, D. & Lipkin, S. M. Future trends in cancer prevention and interception in cancer predisposition syndromes: leveraging insights from high-risk populations. Int. J. Cancer https://doi.org/10.1002/ijc.70674 (2026).
Albini, A. et al. From combination early detection to multicancer testing: shifting cancer care toward proactive prevention and interception. Cancer Prev. Res. 18, 583–602 https://doi.org/10.1158/1940-6207.CAPR-24-0558 (2025).
Fackenthal, J. D. et al. High prevalence of BRCA1 and BRCA2 mutations in unselected Nigerian breast cancer patients. Int. J. Cancer 131, 1114–1123 https://doi.org/10.1002/ijc.27326 (2012).
Zhang, J. et al. Recurrent BRCA1 and BRCA2 mutations in breast cancer patients of African ancestry. Breast Cancer Res. Treat. 134, 889–894 https://doi.org/10.1007/s10549-012-2136-z (2012).
Zheng, Y. et al. Inherited breast cancer in Nigerian women. J. Clin. Oncol. 36, 2820–2825 https://doi.org/10.1200/JCO.2018.78.3977 (2018).
Ansari-Pour, N. et al. Whole-genome analysis of Nigerian patients with breast cancer reveals ethnic-driven somatic evolution and distinct genomic subtypes. Nat. Commun. 12, 6946 https://doi.org/10.1038/s41467-021-27079-w (2021).
Mugo, N. & Contino, G. Genomic landscapes of breast cancer in African populations: a systematic review. NPJ Breast Cancer 11, 91 https://doi.org/10.1038/s41523-025-00809-9 (2025).
Guo, W. et al. Genetic and nongenetic risk factors for breast cancer risk estimation. JAMA Netw. Open 8, e255804 https://doi.org/10.1001/jamanetworkopen.2025.5804 (2025).
Ashi, K. et al. Validation of the Nigerian breast cancer study model for predicting individual breast cancer risk in Cameroon and Uganda. Cancer Epidemiol. Biomarkers Prev. 32, 98–104 https://doi.org/10.1158/1055-9965.EPI-22-0869 (2023).
Pitt, J. J. et al. Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular features. Nat. Commun. 9, 4181 https://doi.org/10.1038/s41467-018-06616-0 (2018).
Mai, P. L. et al. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort. Cancer 122, 3673–3681 https://doi.org/10.1002/cncr.30248 (2016).
Marabelli, M., Cheng, S. C. & Parmigiani, G. Penetrance of ATM gene mutations in breast cancer: a meta-analysis of different measures of risk. Genet. Epidemiol. 40, 425–431 https://doi.org/10.1002/gepi.21971 (2016).
Dhawan, A. et al. Cancer and overgrowth manifestations of PTEN hamartoma tumor syndrome: management recommendations from the International PHTS Consensus Guidelines Working Group. Clin. Cancer Res. 31, 1754–1765 https://doi.org/10.1158/1078-0432.Ccr-24-3819 (2025).
Ryan, C. E. et al. Germline CDH1 variants and lifetime cancer risk. JAMA 332, 722–729 https://doi.org/10.1001/jama.2024.10852 (2024).
Collaborative Group on Hormonal Factors in Breast Cancer. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol. 13, 1141–1151 https://doi.org/10.1016/S1470-2045(12)70425-4 (2012).
Jung, A. Y. et al. Distinct reproductive risk profiles for intrinsic-like breast cancer subtypes: pooled analysis of population-based studies. J. Natl Cancer Inst. 114, 1706–1719 https://doi.org/10.1093/jnci/djac117 (2022).
Clavel-Chapelon, F. & Group, E. N. E. Differential effects of reproductive factors on the risk of pre- and postmenopausal breast cancer. Results from a large cohort of French women. Br. J. Cancer 86, 723–727 https://doi.org/10.1038/sj.bjc.6600124 (2002).
Prince, C. et al. Assessing the causal and independent impact of parity-related reproductive factors on risk of breast cancer subtypes. BMC Med. 23, 530 https://doi.org/10.1186/s12916-025-04375-6 (2025).
Lambertini, M. et al. Reproductive behaviors and risk of developing breast cancer according to tumor subtype: a systematic review and meta-analysis of epidemiological studies. Cancer Treat. Rev. 49, 65–76 https://doi.org/10.1016/j.ctrv.2016.07.006 (2016).
Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet 360, 187–195 https://doi.org/10.1016/S0140-6736(02)09454-0 (2002).
Islami, F. et al. American Cancer Society’s report on the status of cancer disparities in the United States, 2023. CA Cancer J. Clin. 74, 136–166 https://doi.org/10.3322/caac.21812 (2024).
John, E. M. et al. Reproductive history, breast-feeding and risk of triple negative breast cancer: The Breast Cancer Etiology in Minorities (BEM) study. Int. J. Cancer 142, 2273–2285 https://doi.org/10.1002/ijc.31258 (2018).
Fitzpatrick, D., Pirie, K., Reeves, G., Green, J. & Beral, V. Combined and progestagen-only hormonal contraceptives and breast cancer risk: a UK nested case-control study and meta-analysis. PLoS Med. 20, e1004188 https://doi.org/10.1371/journal.pmed.1004188 (2023).
Niemeyer Hultstrand, J. et al. Hormonal contraception and risk of breast cancer and breast cancer in situ among Swedish women 15-34 years of age: a nationwide register-based study. Lancet Reg. Health Eur. 21, 100470 https://doi.org/10.1016/j.lanepe.2022.100470 (2022).
Kawai, M., Malone, K. E., Tang, M. T. & Li, C. I. Height, body mass index (BMI), BMI change, and the risk of estrogen receptor-positive, HER2-positive, and triple-negative breast cancer among women ages 20 to 44 years. Cancer 120, 1548–1556 https://doi.org/10.1002/cncr.28601 (2014).
Kawai, M., Malone, K. E., Tang, M. T. & Li, C. I. Active smoking and the risk of estrogen receptor-positive and triple-negative breast cancer among women ages 20 to 44 years. Cancer 120, 1026–1034 https://doi.org/10.1002/cncr.28402 (2014).
National Cancer Institute. SEER*Stat Databases: SEER November 2025 Submission https://seer.cancer.gov/data-software/documentation/seerstat/nov2025/ (2026).
来源:Nature 健康护理主题 · nature.com